Estrella Immunopharma (NASDAQ:ESLA) Trading Up 26.5% – Should You Buy?
by Scott Moore · The Cerbat GemEstrella Immunopharma, Inc. (NASDAQ:ESLA – Get Free Report)’s share price was up 26.5% on Tuesday . The stock traded as high as $1.95 and last traded at $1.72. Approximately 1,226,373 shares traded hands during mid-day trading, an increase of 2,097% from the average daily volume of 55,822 shares. The stock had previously closed at $1.36.
Analysts Set New Price Targets
Several research analysts have recently weighed in on ESLA shares. Wall Street Zen raised shares of Estrella Immunopharma from a “sell” rating to a “hold” rating in a report on Saturday, January 31st. D. Boral Capital reaffirmed a “buy” rating and issued a $8.00 price target on shares of Estrella Immunopharma in a report on Monday, February 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Estrella Immunopharma in a report on Wednesday, January 28th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $8.00.
Get Our Latest Stock Report on Estrella Immunopharma
Estrella Immunopharma Price Performance
The firm has a market cap of $78.94 million, a P/E ratio of -5.29 and a beta of 0.58. The stock has a 50 day moving average of $1.20 and a 200 day moving average of $1.50.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in Estrella Immunopharma by 1,045.7% in the fourth quarter. Renaissance Technologies LLC now owns 122,468 shares of the company’s stock valued at $191,000 after acquiring an additional 111,779 shares during the last quarter. Geode Capital Management LLC increased its stake in Estrella Immunopharma by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after acquiring an additional 8,318 shares during the last quarter. Marshall Wace LLP bought a new position in Estrella Immunopharma in the fourth quarter valued at $88,000. XTX Topco Ltd increased its stake in Estrella Immunopharma by 376.9% in the fourth quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after acquiring an additional 39,099 shares during the last quarter. Finally, State Street Corp increased its stake in Estrella Immunopharma by 93.5% in the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock valued at $67,000 after acquiring an additional 20,900 shares during the last quarter. Institutional investors own 0.35% of the company’s stock.
Estrella Immunopharma Company Profile
Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.